Array BioPharma Receives FDA Breakthrough Therapy Designation For Braftovi

Array BioPharma Inc. received Breakthrough Therapy Designation from the FDA for encorafenib (BRAFTOVI), in combination with binimetinib (MEKTOVI) and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).